Petros Isaakidis

Petros Isaakidis

Auto-generated profile, based on publicly available information

Petros Isaakidis

Affiliations Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa, Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet
Verified
Journal Article
Closed access
NANafees Ahmad
Nafees Ahmad
SAShama D Ahuja
Shama D Ahuja
OAOnno W. Akkerman
Onno W. Akkerman
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
LALaura F Anderson
Laura F Anderson
DMDick Menzies
Dick Menzies

11 July 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EHElizabeth P. Harausz
Elizabeth P. Harausz
AGAnthony J. Garcia-Prats
Anthony J. Garcia-Prats
SLStephanie Law
Stephanie Law
HSHendrik Simon Schaaf
Hendrik Simon Schaaf
TKTamara Kredo
Tamara Kredo
FMfor the Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB
for the Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB
An estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optimal treatment for these children. To inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB treatment guidelines, we performed a systematic review and individual patient data (IPD) meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, PsychINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished data, we reviewed conference abstracts, contacted experts in the field, and requested data through other routes, including at national and international conferences and through organizations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a minimum of three children (aged <15 years) who were treated for bacteriologically confirmed or clinically diagnosed MDR-TB, and if treatment outcomes were reported. The search yielded 2,772 reports; after review, 33 studies were eligible for inclusion, with IPD provided for 28 of these. All data were from published or unpublished observational cohorts. We analyzed demographic, clinical, and treatment factors as predictors of treatment outcome. In order to obtain adjusted estimates, we used a random-effects multivariable logistic regression (random intercept and random slope, unless specified otherwise) adjusted for the following covariates: age, sex, HIV infection, malnutrition, severe extrapulmonary disease, or the presence of severe disease on chest radiograph. We analyzed data from 975 children from 18 countries; 731 (75%) had bacteriologically confirmed and 244 (25%) had clinically diagnosed MDR-TB. The median age was 7.1 years. Of 910 (93%) children with documented HIV status, 359 (39%) were infected with HIV. When compared to clinically diagnosed patients, children with confirmed MDR-TB were more likely to be older, to be infected with HIV, to be malnourished, and to have severe tuberculosis (TB) on chest radiograph (p < 0.001 for all characteristics). Overall, 764 of 975 (78%) had a successful treatment outcome at the conclusion of therapy: 548/731 (75%) of confirmed and 216/244 (89%) of clinically diagnosed children (absolute difference 14%, 95% confidence interval [CI] 8%–19%, p < 0.001). Treatment was successful in only 56% of children with bacteriologically confirmed TB who were infected with HIV who did not receive any antiretroviral treatment (ART) during MDR-TB therapy, compared to 82% in children infected with HIV who received ART during MDR-TB therapy (absolute difference 26%, 95% CI 5%–48%, p = 0.006). In children with confirmed MDR-TB, the use of second-line injectable agents and high-dose isoniazid (15–20 mg/kg/day) were associated with treatment success (adjusted odds ratio [aOR] 2.9, 95% CI 1.0–8.3, p = 0.041 and aOR 5.9, 95% CI 1.7–20.5, p = 0.007, respectively). These findings for high-dose isoniazid may have been affected by site effect, as the majority of patients came from Cape Town. Limitations of this study include the difficulty of estimating the treatment effects of individual drugs within multidrug regimens, only observational cohort studies were available for inclusion, and treatment decisions were based on the clinician’s perception of illness, with resulting potential for bias. This study suggests that children respond favorably to MDR-TB treatment. The low success rate in children infected with HIV who did not receive ART during their MDR-TB treatment highlights the need for ART in these children. Our findings of individual drug effects on treatment outcome should be further evaluated.

1 August 2015 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
PIP. Isaakidis
P. Isaakidis
ECE. C. Casas
E. C. Casas
MDM. Das
M. Das
XTX. Tseretopoulou
X. Tseretopoulou
ENE. E. Ntzani
E. E. Ntzani
NFN. Ford
N. Ford
BACKGROUND: The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing in high human immunodeficiency virus (HIV) prevalence settings, with high associated mortality. Treatment outcomes in HIV-co-infected adults and children are poorly documented. OBJECTIVE: To systematically assess treatment outcomes among HIV–MDR-TB co-infected patients. METHODS: We searched two databases and the proceedings of an annual international conference up to November 2014 for studies reporting on major clinical outcomes among HIV–MDR-TB-co-infected adults and children, and pooled the results using random-effects meta-analysis. RESULTS: Of 4812 abstracts and articles screened, 30 studies providing data on 2578 adults and 147 children were included. Overall pooled treatment success was 56.9% (95% confidence interval [CI] 46.2–67.6), 49.9% (95%CI 38.5–61.2) among adults and 83.4% (95%CI 74.7–92) among children. Mortality was 38% in adults (95%CI 28–48.1) and 11.4% (95%CI 5.8–17.1) in children. Loss to follow-up was higher among adults (16.1%, 95%CI 9–23.2) than among children (3.9%, 95%CI 0.9–6.9). Adverse events were experienced by the majority of patients; however, this was inconsistently documented. The use of fluoroquinolones, aminoglycosides and Group IV drugs appeared to be associated with treatment success. CONCLUSION: The proportion of HIV–MDR-TB-co-infected patients achieving treatment success was similar to success rates reported among MDR-TB patients in general, regardless of HIV status; however, mortality was higher, particularly among adults, highlighting the need for early diagnosis and more effective treatment regimens.

1 May 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
GFGabriella Ferlazzo
Gabriella Ferlazzo
EMErika Mohr
Erika Mohr
CLChinmay Laxmeshwar
Chinmay Laxmeshwar
CHCatherine Hewison
Catherine Hewison
JHJennifer Ann Hughes
Jennifer Ann Hughes
PIPetros Isaakidis
Petros Isaakidis

10 July 2013 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
PIPetros Isaakidis
Petros Isaakidis
SRSheela Rangan
Sheela Rangan
APAnagha Pradhan
Anagha Pradhan
JLJoanna Ladomirska
Joanna Ladomirska
TRTony Reid
Tony Reid
KKKarina Kielmann
Karina Kielmann

1 November 2013 in Public Health Action
Verified
Journal Article
Closed access
Anthony HarriesAnthony Harries
Anthony Harries
SSSrinath Satyanarayana
Srinath Satyanarayana
AKAjay Kumar
Ajay Kumar
SNSharath Burugina Nagaraja
Sharath Burugina Nagaraja
PIP. Isaakidis
P. Isaakidis
AKA. Kapur
A. Kapur
The global burden of diabetes mellitus (DM) is immense, with numbers expected to rise to over 550 million by 2030. Countries in Asia, such as India and China, will bear the brunt of this unfolding epidemic. Persons with DM have a significantly increased risk of developing active tuberculosis (TB) that is two to three times higher than in persons without DM. This article reviews the epidemiology and interactions of these two diseases, discusses how the World Health Organization and International Union Against Tuberculosis and Lung Disease developed and launched the Collaborative Framework for the care and control of TB and DM, and examines three important challenges for care. These relate to 1) bi-directional screening of the two diseases, 2) treatment of patients with dual disease, and 3) prevention of TB in persons with DM. For each area, the gaps in knowledge and the priority research areas are highlighted. Undiagnosed, inadequately treated and poorly controlled DM appears to be a much greater threat to TB prevention and control than previously realised, and the problem needs to be addressed. Prevention of DM through attention to unhealthy diets, sedentary lifestyles and childhood and adult obesity must be included in broad non-communicable disease prevention strategies. This collaborative framework provides a template for action, and the recommendations now need to be implemented and evaluated in the field to lay down a firm foundation for the scaling up of interventions that work and are effective in tackling this dual burden of disease.